AU622459B2

AU622459B2 – Process for producing hegf
– Google Patents

AU622459B2 – Process for producing hegf
– Google Patents
Process for producing hegf

Download PDF
Info

Publication number
AU622459B2

AU622459B2
AU38145/89A
AU3814589A
AU622459B2
AU 622459 B2
AU622459 B2
AU 622459B2
AU 38145/89 A
AU38145/89 A
AU 38145/89A
AU 3814589 A
AU3814589 A
AU 3814589A
AU 622459 B2
AU622459 B2
AU 622459B2
Authority
AU
Australia
Prior art keywords
hegf
coli
culture
medium
gene
Prior art date
1988-07-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Application number
AU38145/89A
Other versions

AU3814589A
(en

Inventor
Masatoshi Murai
Junichi Yano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Nippon Shinyaku Co Ltd

Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1988-07-15
Filing date
1989-07-14
Publication date
1992-04-09

1989-07-14
Application filed by Nippon Shinyaku Co Ltd
filed
Critical
Nippon Shinyaku Co Ltd

1990-01-18
Publication of AU3814589A
publication
Critical
patent/AU3814589A/en

1992-04-09
Application granted
granted
Critical

1992-04-09
Publication of AU622459B2
publication
Critical
patent/AU622459B2/en

2009-07-14
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

C12N15/09—Recombinant DNA-technology

C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

C12N15/70—Vectors or expression systems specially adapted for E. coli

C12N15/71—Expression systems using regulatory sequences derived from the trp-operon

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

C07K14/475—Growth factors; Growth regulators

C07K14/485—Epidermal growth factor [EGF] (urogastrone)

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K2319/00—Fusion polypeptide

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K2319/00—Fusion polypeptide

C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K2319/00—Fusion polypeptide

C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K2319/00—Fusion polypeptide

C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Description

i li .il-.d eit
AUSTRALIA
4 PATENTS ACT 1952 COMPLETE SPECIFICATION Form
(ORIGINAL)
FOR OFFICE USE Short Title: Int. Cl: Application Number: Lodged: 040 Complete Specification-Lodged: Accepted: Lapsed: Published: S Priority: Related Art: TO BE COMPLETED BY APPLICANT :1 4 4 4 Name of Applicant: Address of Applicant: NIPPON SHINYAKU CO. LTD.
14, KISSHOIN NISHINOSHO MONGUCHICHO, MINAMI-KU KYOTO 601
JAPAN
GRIFFITH HACK CO., 601 St. Kilda Road, Melbourne, Victoria 3004, Australia.
Actual Inventor: Address for Service: ‘Ott Complete Specification for the invention entitled: PROCESS FOR PRODUCING hEGF.
The following statement is a full description of this invention including the best method of performing it known to me:- 1A- Control of Protein Production in Culture using Expression Vectors comprising trp Promoter The present invention relates to a process for producing human epidermal growth factor (hEGF) efficiently by genetic engineering and vectors therefor.
It has now been ascertained that hEGF is the same substance as -urogastrone. The present invention provides hEGF, useful as an anti-ulcer agent, etc., in good quantities by simple means.
Methods for integrating a gene coding for an objective substance in a vector, transforming E. coli using this vector J cult,’ ng the thus obtained transformant, and recovering and collecting the objective substance from the culture solution, are already known. Methods applicable to trace proteins are described, for example, in: Tacon, Carey, Emetage, S. Molec. Gen. Genet., 177, 427 (1980); Tacon, et. al. Gene 23, 255 (1983); Kawai, et. al. J. Ferment. Technol., 64, 503 (1986); and Oka, et. al. Proc. Natl. Acad. Sci. USA. 82, 7212 (1985).
2- One method comprises creating recombinant DNA containing both a gene encoding an E. coli alkaline phosphatase promoter and a gene encoding a signal peptide under its control and having also integrated a gene encoding hEGF thereby to obtain hEGF (Japanese Published Unexamined Patent Application Nos. 003799/89 and 003800/89). In this method, to increase the yield, incubation conditions have been varied, for example, by culturing at low temperatures prior to inducing protein syr.thesis; or by culturing I under weakly acidic or neutral conditions prior to inducing protein synthesis but culturing under weakly alkaline conditions after the induction of protein synthesis.
In the case of high density cultures accompanied by secrecion and expression in a medium, the prior art involves many defects. For example, it is not possible to freely control he time when the transformed E. coli starts producing hEGF, which also means that it is impossible to proliferate the transformed E. coli sufficiently prior to initiating hEGF production, and that it is, therefore, r impossible for the transformed E. coli to control the progress of r hEGF production, in high density culture (cultures of more than 0D 550 In view of its principle, it was also impossible to apply the batch-feed system (technique for continuous culture while 1 i 4 3 supplementing a medium during the culture) required for high density culture.
It has now been discovered that proliferation of transformed E. coli is inhibited, when it begins to produce hEGF. While the reason is not necessarily clear, it is assumed that great stress would be borne by the transformed E. coli, taking into the phenomenon specific to hEGF that the produced hEGF does not remain in the cytoplasm of the transformed E. coli or in the periplasm (between the inner membrane and the outer membrane), but is secreted. Based on this phenomenon, it is assumed to be because proliferation of the transformed E. coli itself would be inhibited at the same time when hEGF is produced.
Thus, in order to achieve high density culture, it is desirable to be able to initiate the production of hEGF when the transformed E. coli is sufficiently proliferated, i.e. to freely control the time of producing hEGF.
In various aspects, the present invention provides: using a promoter for tryptophan (trp) operon having an ATG initiation codon; controlling hEGF production by the addition of 3 -indoleacrylic acid (IAA); efficient use of the batch-feed system (rate of supplementing a medium to be added is variable);
A-
~l 1 in the batch-feed system above, glucose is used and then glycerol is used, as carbon sources for the supplementing medium in the batch-feed system.
Thus, the present invention broadly provides an expression vector for a protein, comprising: a first DNA sequence encoding said protein, said protein being hEGF, the gene being modified generally to provide codons used in Escherichia coli in high frequency, and repeat sequences associated with nucleotide secondary structure removed; a second DNA sequence encoding a signal peptide and *ee: operatively connected ‘ith the first DNA sequence in the upstream position; and a promoter sequence therefor, the promoter sequence substantially corresponding to an E. coli trp operon promoter having an ATG initiation codon.
S. In an alternative aspect, the present invention provides vectors which, in suitable hosts, can controllably produce human epidermal growth factor (hEGF), control being exerted through the presence of a trp promoter in the vector which is catabolically repressed by tryptophan, but which repression can be lifted by the introduction of 3-indoleacrylic acid, a tryptophan analogue, into the culture.
When using an E. coli alkaline phosphatase promoter, hEGF productivity stops due to the presence of phosphate in the medium.
Transformed E. coli proliferates and during this course, the I ^l iJj 4 A 7 ‘N l^ a).
i ;I; 5 phosphate is consumed and reduced to less than a definite concentration. Then, the E. coli alkaline phosphatase promoter initiates hEGF production. In the prior art, this phenomenon has been controlled by pH and temperature of the culture solution, thereby enhancing the hEGF productivity.
In the present invention, the trp operon promoter is used, instead of the E. coli alkaline phosphatase gene-derived promoter described above.
Preferably, about 50 mg/1 of tryptophan is previously added to medium. As transformed E. coli proliferates, tryptophan is consumed; when tryptophan is reduced to less than a definite concentration, the trp operon promoter begins to act to initiate hEGF production. However, when enough tryptophan is present in the medium, the promoter cannot initiate hEGF production. Furthermore, as will be shown later in the Examples, particularly the transformed E. coli has properties that when it secretes hEGF, its proliferation rate is weakened or its proliferation is discontinued.
S*From these facts, it has been found that the secretion Sexpression plasmid vector bearing the trp promoter used in the present invention is extremely suited to utilize for high density culture of transformed E. coli, since its expression can be strictly controlled easily. That is, in order to increase the amount of -6secreted hEGF to more than 150 mg/1, incubation is performed in the presence of tryptophan; when transformed E. coli is proliferated in a sufficiently high density, IAA is immediately added and the product can be recovered from the medium in a short time (10 to 18 hours).
Further by addition of glycero.l into medium in the batch-feed system in place of glucose or by changing glucose to glycerol on the way of addition, it is possible to ingeniously control the timing for initiating the action of trp promoter, as will be later described.
IAA is a substance having a structure similar to that of tryptophan and is a competetive inhibitor therefor. It has an affinity for the repressor protein stronger than that of tryptophan.
Accordingly, IAA predominantly binds to repressor and prevents the repressor from binding the promoter (operator). Therefore, by .’incorporating IAA into medium, the promoter can act even when tryptophan is present.
Thus, hEGF production can be initiated by addition of IAA at any stage of the culture.
It is known that when proliferation of transformed E. coli is enhanced, hEGF production is proportionally enhanced. The density of transformed E. coli in the medium can be increased by designing the medium itself or by applying the batch-feed system. Therefore, only by starting hEGF production after proliferation of transformed E.
coli is enhanced, can hEGF be collected so ficiently.
k
I
7 In the present invention, techniques used in conventional genetic engineering can be appropriately used. For example, as host E. coli, E. coli K12, widely used, is suitable. Further, as the vector, commercially available plasmids may be used. More preferably, the following E. coli strains can be used in the present invention.
JM101, TB1, HB101, RR1, DH1, MM294, C600galK-, Y1090 (pMC9-deficient strain), as well as derivatives thereof.
In the present invention, for example, the following plasmid and phage DNA can be used: pDR540 (manufactured by Pharmacia Fine Chemicals Inc.), and M13mpl8 and mpl9 (manufactured by Takara Shuzo Co., Ltd).
The following media may be used as basal medium and supplemeniting medium: LB medium (10 g/l bacto-trypton, 5 g/l yeast extract, 5 g/l sodium chloride); M9 medium (6 g/l disodium hydrogenphosphate, 3 g/l potassium dihydrogenphosphate, 0.05 g/l sodium chloride ammonium chloride, 2 mM magnesium sulfate, 0.1 mM calcium chloride); and 4YTM9 medium (M9 medium supplemented with the following components: 32 g/1 bacto-trypton, 20 g/l yeast extract).
Generally speaking, it will be appreciated that any suitable host may be used, such as Saccharomyces cerevisiae and Bacillus subtilis strains, for example.
,:I
~I
0*40
_II
8- In addition, protein is IIEGF, the original genetic, mutated or synthetic sequences or any other nucleotide sequences may be used, provided that the encoded product has hEGF activity, or is a precursor therefor.
Similar considerations apply to the sequence encoding the signal peptide and the trp promoter. It will also be appreciated that, in place of IAA, any suitable tryptophan inhibitor may be used, although competitive, especially tryptophan-analogue, inhibitors are preferred.
The medium can be prepared by adding agar to plate medium in a concentration of 1.5% and to M13 phage upper layer medium in a concentration of For culturing E. coli containing all plasmids, ampicillin is added to the medium in 100 mg/l thereby to prevent the plasmids from being cured.
As restriction enzymes and DNA modifying enzymes used in the present invention, those used in ordinary genetic engineering can be appropriately used. For example, enzymes manufactured by Takara Shuzo Co., Ltd., Toyobo Co., Ltd., Pharmacia Fine Chemicals Inc. and Boehringer Mannheim. In the present invention, these enzymes can be used in accordance with manuals A.
I
I
-9and publications (Molecular Cloning; a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York).
Further for transformation of E. coli, purification of plasmid and purification of phage DNA in the present invention, techniques used in ordinary genetic engineering can be appropriately used. Alternatively, they may follow manuals and publications (Molecular Cloning).
The oligonucleotide in the present invention can be synthesized by appropriately using techniques conventionally applied to ordinary DNA synthesis (for example, triester method).
On the other hand, the oligonucleotide can also be synthesized using commercially available DNA synthesizer (Model 380B, manufactured by Applied Biosystem Inc.).
Further for ligation of the oligonucleotide in the present invention, techniques used in ordinary genetic engineering can be appropriately used. Specifically, for example, 1 pg of each of the synthetic oligonucleotide is phosphorylated in 20 pl of linker kinase buffer (by Molecular Cloning) and then mixed.
After heating at 70*C for 10 minutes, the system is gradually cooled to room temperature over about an hour. Next, the same volume of 1-fold concentration linker kinase buffer as the mixture is added to the mixture and T4 DNA ligase is then added thereto. The mixture is allowed to stand overnight at 16°C. Next, the mixture is heated at 700C for 10 minutes t” inactivate T4 DNA ligase. Thereafter, the buffer is exchanged by the ethanol precipitation method. After cleaving with restriction enzymes at both termini so as to form the objective fragment, fractionation f is- is carried out by 8% polyacrylamide slab gel electrophoresis.
From the gel containing the objective DNA fragment, DNA is purified by extraction with buffer (by Molecular Cloning). Such a technique is a typical example of ligation of oligonucleotide in the present invention.
To determine the amount of hEGF which is the objective product in the present invention, techniques used in ordinary genetic engineering can be appropriately used. Specifically, the hEGF amount can be determined by radioimmunoassay (using the kit manufactured by Amersham Inc.) using, for example, commercially available hEGF (manufactured by Wakunaga Pharmaceutical Co., Ltd., or Amersham Inc.) as standard.
Hereafter, the present invention is illustrated in more detail, with reference to the following Reference Examples and Examples.
Reference Example 1 Production of Secretion Expression Plasmid Synthesis of trp promoter, SD sequence and E. coli alkaline phosphatase signal peptide gene: The trp promoter and SD sequence (Shine-Dalgarno ribosomebound site) utilized were set from T at the -60 position to A at the +26 position when A as the transcription initiation site was made At the 5′-end of T at the -60 position, Hind III cleavage site was provided, taking ligation with vector into account. The E. coli alkaline phosphatase signal peptide gene followed naturally occurring sequence but taking ligation with vector and ligation with hEGF gene into account, GTG of P_ 1 initiation codon was modified to ATG, GCT at the C-terminal was modified to GCG and EcoRI cleavage site was provided at the 3′-end.
The foregoing sequence was synthesized by dividing into 8 oligonucleotides, which were ligated in a conventional manner. The product was purified as Hind III-EcoR I DNA fragment. Further this fragment was inserted between Hind III-EcoR I cleavage sites of Ml3mpl8 phage replicative form DNA and its nucleotide sequence was confirmed by the dideoxy sequencing method (Fig. 1).
nthesis of hEGF gene The sequence of hEGF gene was devised based on the amino acid sequence of natural hEGF. Upon device of the sequence, the following 3 points were taken into account: use of codon used with high frequency in E. coli, removal of repeating sequence that can take a secondary structure and provision of Sph I cleavage site in the middle of gene necessary for gene ligation.
Specifically, hEGF gene was produced as the EcoR I-Sac I DNA fragment composed of 21 oligonucleotides.
Firstly, 11 oligonucleotides constituting the former part of the EcoR I-Sac I DNA fragement was synthesized and ligated in a conventional manner, which was then inserted between the EcoR I-Sph I cleavage site of M1 3 mpl8 phage replicative form DNA. The nucleotide sequence was confirmed by the dideoxy sequencing method.
Next, 10 oligonucleotides constituting the EcoRI Sac I DNA fragment was synthesized and ligated in a conventional manner, which was then inserted between the Sph I-Sph I cleavage site of M13mpl8 phage replicative form DNA. The nucleotide sequence was confirmed by the dideoxy sequencing method.
gM L k NA fr g e t w s y t e i ed a d l g t d n a c n en i n l m nn r h c -12- From the respective recombinant M13 phage replicative form DNAs, the EcoR I-Sph I DNA fragment and the Sph I-Sac I DNA fragment were excised and ligated with each other to produce hEGF gene.
In the completed hEGF gene, 5′-end constitutes the EcoRI cleavage site and this portion :responds to asparagine of the N-terminal amino acid. Its 3′-end constitutes the Sac I cleavage site and is in the form that termination codons TGA and TAG follows just therebefore. The EcoR I-Sac I DNA fragment of the S ligated hEGF gene was inserted into the EcoR I-Sac I cleavage site of Ml3mpl8 phage replicative form DNA. The nucleotide sequence was again confirmed by the dideoxy sequencing method.(Fig. 2).
i Production of secretion expression plasmid t Firstly, the EcoR I cleavage site of pDR540 (manufactured by Pharmacia Fine Chemicals Inc.) was erased in a conventional manner using DNA polymerase Klenow fragment and T4 ligase to produce pDR540E- plasmid.
Next, linker synthesized and ligated in a conventional manner was inserted into the BamH I cleavage site of this pDR540E- DNA and, cleavage sites with EcoR I, Xho I, Sac I and Pvu II were newly introduced therein.
Furthermore, trp A terminator sequence (manufactured by S Pharmacia Fine Chemicals Inc.) was inserted into this Pvu II cleavage site to prepare pATGt plasmid. The EcoR I-Sac I DNA fragment containing synthetic hEGF gene was inserted between the EcoR I cleavage site and the Sac I cleavage site of this pATGt plasmid DNA to prepare pBT19 plasmid.
i C I_ -13- Next, the Hind III-EcoR I DNA fragment containing trp promoter, SD sequence and E. coli alkaline phosphatase signal peptide gene was inserted between the Hind III cleavage site and the EcoR I cleavage site of pBT19 to produce hEGF secretion expression plasmid pBT23 (Fig. 3 and Fig. 4).
Reference Example 2 Expression of EGF and its Distribution Using pBT23 E. coli C600galK- was transformed to obtain transformed E. c. li containing pBT23.
This pBT23-containing C600galK- strain was shake cultured in 0.1 litre of LB medium overnight, which was made preculture S solution. The preculture solution, 4 ml, was inoculated (2% inoculation) on 0.2 lite’ of M9 medium (containing 5 g/l Casamino acid, 2 g/l glucose, 10 mg/l vitamin B 1 and 100 mg/1 ampicillin) charged in a shake flask of a 0.5 liter volume followed by shake culture at 37*C at 125 times/minute. At the exponential growth plase (in this case, OD 550 was about 3-indoleacrylic acid (IAA) S550 was added in a concentration of 20 mg/l to induce trp promoter.
The sample was taken 1, 2, 4, 6, 8 and 24 hours after the initiation of culture and centrifuged to separate the medium and the cell component from each other. From the cells, their periplasm fraction was further separated by the osmotic shock l procedure. The amount-of hEGF in the medium and the periplasm was determined by radioimmunoassay (kit manufactured by Amersham Inc.). The results are shown in Table 1.
:I r*.
-14- Table 1. Distribution of hEGF Culture Amount of hEGF (mg/1) Time Periplasm Medium 1 0.011 0.017 2 0.016 0.030 4 0.022 0.190 6 0.017 0.430 8 0.014 0.490 24 0.004 0.730 The hEGF amount in the medium reached the maximum or 0.73 mg/l, 24 hot.rs after the initiation of the culture. The hEGF accumulated in the periplasm reached the maximum 4 hours after the culture was initiated but its amount was about 0.02 mg/l at maximum.
hEGF was reduced and almost lost 24 hours after.
From these facts, it was confirmed that the secreted hEGF was mostly present in the medium. Thus, in the following runs, the amount of hEGF produced was measured only in the medium.
Reference Ekample 3 Study on Host E. coli Strain Using pBT23 DNA, E. coli HB101, RR1, DH1, MM294, Y1090 (pMC9-deficient strain), JM101 and TB1 strains were transformed to obtain E. coli transformants containing the respective pBT23.
The transformants were cultured under the same conditions as in Reference Example 2, also including the previous C600galKtransformant. Induction of trp promoter with IAA was carried out hours after the culture was initiated. At this point in time and 24 hours after, the amount of hEGF in the medium was measured i (Table 2).
Table 2. Amount of hEGF in various E. coli transformants Amount of hEGF (mg/1) E. coli Strain 9.5 Hours After 24 Hours After C600galK- 0.54 1.25 HB101 0.54 1.25 RR1 1.23 0.93 DH1 0.64 0.45 MM294 0.28 0.50 Y1090 (pMC9-deficient strain) 0.03 0.02 JM101 0.81 0.67 TB1 2.30 4.00 Among the 8 E. coli transformants, TB1 provides the largest -roduction amount and reached 4 mg/l. Then, C600galK- and HB101 were the second largest and both reached 1.25 mg/l. These strains were considered to be suitable for producing of hEGF.
Reference Example 4 Study on Timing for Inducing trp Promoter Using pBT23-containing HB101 transformant, culture was carried out under the same conditions as in Reference Example 2. IAA was added in a concentration of 20 mg/l in the intermediate, later and stationary stages of exponential growth phase, respectively to examine the hEGF amount in the medium. The results are shown in Table 3.
1 i -16- Table 3 Timing for inducing trp promoter and hEGF production Amount of hEGF (mg/1) Culture Exponential Growth Plase Time Intermediate Stage Later Stage Stationary phase 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 (added with IAA) 0.18 0.16 0.14 0.65 0.43 0.33 (added with IAA) 1.69 0.83 0.63 2.28 0.98 0.90 2.63 1.10 1.10 2.41 1.63 1.66 24.0 5.75 8.95 8.95 It was noted that the addition of IAA in the later stage of the exponential growth phase or stationary phase produced larger amounts of hEGF production.
Reference Example Using pBT23-containing HB101 transformant, culture was carried out under the same conditions as in Reference Example 2 (except that media shown in Table 4 were used). When 4YTM9, M9-1 and M9-2 were used as media, IAA was added 5.5 hours after and when M9-3 and M9-4 were used, 9 hours after, in a concentration of 20 mg/l.
The hEGF amount in each medium was measured 9 and 24 hours after the culture was initiated.
I L 4YM9 M9 medium Bacto-trypton 32 Yeast extract 20 -17- Table 4 Composition of medium M9-1 M9-2 4g/l Casamino acid 10 g/1 5 g/1 g/l Glucose 5 g/l Vitamin B 1 10 mg/ M9-3 -2 g 2 g/1l 4- M9-4 2 g– 2 g/l Ampicillin 100 mg/1 4- 4wherein signifies ‘same as previous column’.
Table 5 Composition of medium and amount of hEGF production Amount of hEGF (mg/1) Medium 9 Hours After 24 Hours After 4YTM9 0.04 0.09 M9-1 0.68 0.70 M9-2 1.98 1.69 M9-3 3.03 7.25 M9-4 0.91 2.38 When M9-3 medium (containing 5 g/l Casamino acid and 2 g/1 glucose) was used, the hEGF amount reached the maximum (7.25 mg/1). It was also noted that in the medium composed mainly of natural components (for example, yeast extract, Bacto-trypton) containing large amounts of tryptophan, the hEGF production amount was small.
SReference Example 6 Control of trp Promoter b Tryptophan in Medium The culture in Reference Examples described above contains no tryptophan in the media and is the natural induction f I ii~:Lil ~1 L -I 1I -18system in which induction of trp promoter occurs at the time when tryptophan derived from the precuture solution was reduced to less than a definite concentration as E. coli was proliferated.
In this system, addition of the inducer IAA could increase the production of hEGF but could not switch the trp promoter induction on directly.
Thus, tryptophan was previously added to medium to see if induction from trp promoter could be inhibited and assuming this is the case, to see if it was possible to release the inhibition by adding IAA.
The amounts of tryptophan added were 1, 3, 10, 20, 30 and mg/l and IAA was also added in concentrations shown in Table 6.
Using pBT-23 containing HB101 transformant, culture was carried out under the same conditions as in Reference Example 2. IAA was added 5 hours after the culture was initiated. The hEGF amount in the medium was determined. The results are shown in Table 6.
!i i i K. -19- Table 6 Concentration of tryptophan in medium and hEGF production amount Concentration Concentof ration Trypto- of 1 Amount of hEGF (mq/1) No.
1) 2) 3) 4) 5) 6) 7) 8) 9) (11) (12) (13) (14) (15) (16) phan (mg/1) 0 0 1 1 3 3 10 10 20 20 20 20 30 30 40 40
IAA
(mg/1) 0 20 0 20 0 20 0 20 0 20 40 80 0 80 0 90 Hour Hours After After <0.08 0.22 <0.08 0.27 <0.08 0.27 <0.08 0.26 <0.08 0.29 <0.08 0.27 <0.08 <0.08 <0.08 0.08 0.08 <0.08 <0.08 <0.08 <0.08 <0.08 <0.08 <0.08 <0.08 <0.08 <0.08 <0.08 <0.08 <0.08 <0.08 <0.08 Hours After 1.44 0.97 1.18 1.16 1.09 1.09 0.66 0.69 0.35 0.35 0.45 .0.45 0.42 0.42 0.43 0.37 Hours After 2.15 1.46 1.84 2.04 1.74 1.94 0.96 1.13 0.46 0.71 0.82 0.57 0.47 0.79 0.51 0.60 9 11 24 Hours Hours Hours After After After 2.68 3.75 1.75 2.45 2.31 3.45 2.25 1.71 1.65 0.53 1.31 1.38 1.04 0.60 1.13 0.60 1.07 2.40 4.33 3.80 4.58 3.25 2.68 2.55 0.67 2.00 2.01 1.34 0.86 1.30 0.81 1.38 6.35 9.75 7.75 12.50 9.50 10.50 8.75 8.00 1.03 7.90 7.30 3.60 1.33 2.09 1.41 2.15 11 '4 When the concentration of tryptophan added in the medium was Sless than 10 mg/l, the hEGF production amount was 6 to 10 mg/l, whereas when the concentration of tryptophan was 20 to 40mg/1, the hEGF production amount was as greatly reduced as 1 to mg/l. It was thus noted that tryptophan of more than the definite concentration inhibited production of hEGF. Further in the case that the concentration of tryptophan was mg/l, the hEGF production amount increased by about 8 times by adding 20 or 40 mg/l of IAA. When 80 mg/1 of IAA was added, however, the hEGF production amount increased merely by about 4 times. When the concentration of tryptophan was 30 to 40 mg/l, an increase of the hEGF production amount by addition of 80 mg/l of IAA was as small as about 1.5 time. From the foregoing results, it was confirmed that the addition of tryptophan in an appropriate amount (20 mg/1 in this example) inhibited the induction from trp promoter and the addition of IAA (20 to 40 mg/i) released the inhibition by tryptophan to switch trp promoter on. It was also noted that the addition of tryptophan in a trace amount promoted proliferation of E. coli transformants (the cell amount becomes 1.5 to 2 times by adding 10 to 40 mg/l of tryptophan). It was further noted that the addition of IAA in an excess amount such as more than mg/l inhibited proliferation of E. coli, resulting in reduction in the hEGF production amount. The foregoing results are summarized below. Almost all of the objective hEGF are secreted in the culture solution by sufficient incubation. HB101, TB1 or C600galK- are suitable as host E. coli strains. Induction of trp promoter by IAA is optimum when added at the later growth phase. Medium supplemented with 5 g/1 Casamino acid, 2 g/l i hoeetehG rdcinaon nrae eeyb bu 21 glucose and 10 mg/l vitamin B 1 is appropriate as the medium. By adding IAA, induction of trp promoter is possible, even though tryptophan is present in the medium. Assuming that high density culture in a jar fermenter is enabled in a large scale using these facts as indices, the following experiments were carried out. Further in order to withstand the large scale experiment, purification of hEGF in the culture supernatant of E. coli was examined and the following method was discovered. Experiment 1 Purification of hEGF Adsorption of cation exchange resin manufactured by Biorad Inc.) (pH 3.0)--elution (ammonium acetate, pH dialysis (ammonium acetate, pH Anion exchange column chromatography (Q-Sepharose [Trade Mark] Fast Flow: manufactured by Pharmacia Fine Chemicals Inc., (ammonium acetate, pH Reversed phase (C 18 column chromatography (PepRPC: manufactured by Pharmacia Fine Chemicals Inc., 0.1% trifluoroacetic acid/acetonitrile) -freeze drying According to this method, the overall steps can be performed in 2 to 4 days. In addition, the method does not involve gel filtration chromatography conventionally used so that scaling up is easy. For example, 10 mg of purified hEGF could be obtained from liters of the culture supernatant by this method. The purified hE F had the same amino acid sequence as in the Vi L; 41^ ir 1 1 1 i -22natural one and had the same N-terminal amino acid sequence as in the natural one. Furthermore, the purified hEGF showed biological activity in the following experiment. Experiment 2 Binding ALilitv to EGF Receptor Following the procedure described below, binding ability of the purified hEGF to human cell surface EGF receptor was confirmed. Human A43 ells were suspended in Dulbecco's modified Eagle medium (DMEM medium: manufactured by Nissui Co., Ltd.) containing fetal calf serum (manufactured by Gibco Co., Ltd.) in 104 cells/ml. The cell suspension was charged in a 24 well culture plate in 1 ml each per well followed by culturing at 37*C for 24 hours in 5% CO 2 After the cells were washed twice with DMEM medium binding buffer containing 50 mM N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES, pH 6.5) and 0.1% bovine serum albumin (BSA: manufactured by Sigma Inc.), 0.3 ml of the 125 binding buffer containing 0.2 ng/ml of 1 2 5 I-labeled hEGF (manufactured by Amersham Inc.) and 0.1 to 10,000 ng/ml of hEGF were added to the cells. After allowing to stand at room temperature for 1 hour, the cells were washed twice with the binding buffer and 0.2M sodium hydroxide solution was added in 0.3 ml each per well to lyse the 125 cells. Then, radioactivity of I-labeled hEGF bound to EGF receptor was measured. The results are shown in Table 7. 1i -23- Table 7 Binding ability of purified hEGF to human EGF receptor hEGF Rate of Binding Inhibition ng/well/104 cells [purified hEGF] 0.1 0 1 8 38 100 82 1,000 10,000 98 From the results above, it was confirmed that the purified hEGF had binding ability to EGF receptor of human culture cells. Experiment 3 Cell Growth Accelerating Activity Following the method described below, the cell growth accelerating activity of the purified hEGF was confirmed. Mouse Swiss 3T3 cells were suspended in DMEM medium containing 10% fetal calf serum in 105 cells/ml. The cell suspension was charged in a 24 well culture plate in 1 ml each per well and cultured at 37°C in 5% CO 2 until the cells reached the intermediate stage of the exponential growth phase. The medium was exchanged with DMEM medium containing 0.2% fetal calf serum followed by further culturing at 37*C in 9% CO 2 When almost all cells reached the stationary phase, hEGF was added and culture was continued for further 8 hours. [Methyl-3 H thymidine (247.9 GBq/mmol; manufactured by Amersham Inc.) was added in 0.5 pCi each per well. After culturing for 24 hours, S-24radioactivity of C3H] thymidine incorporated into the cells was determined. The results are shown in Table 8. Table 8 Cell growth accelerating activity of purified hEGF Concentration Intake of 3 HJ Thymidine (ng/ml) (cpm) Proportion 0.0 2864 1.00 0.3 3671 1.28 3753 1.31 4742 1.66 From the foregoing results, the cell growth accelerating S activity of the purified hEGF was confirmed. Experiment 4 S Inhibition of Acid Formation in Guinea Pig Gastric Wall Cell Following the method described below, the inhibiting action of the purified hEGF against formation of gastric juice in 14 isolated wall cells was confirmed using C-aminopyrine (AP) accumulation as the index. After isolated wall cell suspension (1.80 x 10 cells/ml, Hanks solution containing 0.2% BSA (manufactured by Nissui Co., Ltd.)) was kept at 370C for 20 minutes in 100% oxygen flow, 0.1 14 1 Ci C-AP (4.37 GBq/mmol; manufactured by Amersham Inc.), purified hEGF and 3 M of histamine (manufactured by Nakarai Chemical Co., Ltd.) or 1 mM dibutylyl cyclic-AMP (dbc-AMP, manufactured by Sigma Inc.) as a stimulant were added to the suspension and the mixture was again kept at the same temperature. I l i j Sixty minutes after, 4 ml of ice-cooled Hanks solution was added to the mixture. Then centrifugation at low speed at 4 0 C was carried out to stop the reaction. The cells were lysed by adding 0.3 ml of 2M sodium hydroxide solution thereto. After neutralizing with 2M hydrochloric acid, its radioactivity was measured by liquid scintillation counter. Accumulation of 1C-AP was determined by making as 100% the value obtained by subtracting the control value from the intake value upon the stimulation and the activity of the purified hEGF was expressed by stimulation. The results are shown in Table 9. Table 9 Inhibitory activity of purified hEGF against acid formation Stimulation Histamine 3 tM 100 EGF 1 nM 105 EGF 10 nM 38.1 EGF 100 nM 23.1 dbc-AMP 1 mM 100 EGF 1 nM 106 EGF 10 nM 82.1 EGF 100 nM -50.8 From the above results, it was confirmed that the purified hEGF also had the activity of inhibiting formation of gastric juice in guinea pig gastric wall cells by stimulation of both SI j' -26histamine and dbc-AMP. Example 1 Batch System Based on the various findings obtained by the flask culture described above, culture was performed in a large scale, using a jar fermenter of a 10 liter volume. As thejar fermenter, a desk top jar fermenter of a 10 liter volume manufactured by Oriental Yeast Co., Ltd. was used. The jar fermenter was equipped with a control device for regulating pH and dissolved oxygen concentration in medium. HB101 was used as host. Preculture was performed in LB medium and 2% of the preculture solution was inoculated. As medium, 6 liters of M9 medium (containing 5 g/l Casamino acid, 2 g/l glucose, 10 mg/l vitamin B 1 and 100 mg/l ampicillin) was used. Incubation was carried out under conditions of an aeration amount of 1 vvm (volume/volume/minutes; feeding the same amount of air as the culture volume per minute with a air compressor; 6 liters/minute in this case) at 37*C, a dissolved oxygen concentration of 4 ppm (which was controlled by varying the rotation speed of agitation wings between 100 and 1000 rpm), pH of 7.0 (which was S controlled by dropwise adding 4M sodium hydroxic solution), and automatic defoaming (defoaming was conducted by detecting a foamed state with a sensor in the upper part of the fermenter and automatically adding a silicone type antifoaming agent dropwise). IAA was added 4.5 hours after and its addition concentration was mg/l. For control, flask culture was carried out in the same i -27medium composition using the same preculture solution under the same conditions as in Reference Example 2. The results are shown in Fig. In both fermenter culture and flask culture, hEGF production started 4 hours after and continued almost in the same amount up to 9 hours after. However, 24 hours after, 9 mg/l of production was noted in the flask culture whereas in the fermenter culture, 2 mg/l of production which was almost the same as that 9 hours after was merely noted. Therefore, it is understood that it was impossible to improve the hEGF production amount in conventional batch system. This is believed to be because, in the fermenter culture, the dissolved oxygen amount and pH in the medium were kept constant and the optimum conditions for proliferation of E. coli were always provided so that tryptophan in the medium was consumed and reduced to less than a definite concentration; when trp promoter Sbegan to work, nutrient sources (carbon sources, nitrogen sources, etc.) in the medium were exhausted. Thus, as described below, the fed-batch system in which a fresh medium is continuously supplemented during the course of culture was attempted. Example 2 Fed-Batch System Part 1 Under the same culture conditions as in Example 1, a supplementing medium (M9 medium containing 20 g/l Casamino acid, 200 g/l glucose, 10 mg/l vitamin Bl, 100 mg/1 ampicillin and mg/l IAA) was supplemented at a rate of 30 ml/hr for 24 hours -28using a tube pump, at the same time when IAA was added. For control, flask culture was also carried out. The results are shown in Fig. 6. In the fermenter culture, hEGF production was increased from 6 hours after and showed 25 mg/l 9 hours after and 55 mg/l 24 hours after, which was about 25 times that of the batch system in Example 1. However, the maximum was still about 55 mg/1 and cell proliferation was about 6 at OD 550 which results were much farther than the contemplated results in high density culture. Thus, further study was made. It is known that by previously adding tryptophan in medium, the cell amount increases. Therefore, tryptophan was added to basal medium to inhibit the action of trp promoter so that it was attempted to increase the cell amount. In this case, it was recognized that when tryptophan remained in the medium, it inhibited the action of trp promoter when IAA was added. It was thus desired that tryptophan had been degraded when IAA was added. On the other hand, glycerol does not cause catabolite repression, unlike glucoseT It is also known that when catabolite repression is lost,- tryptophanase (tryptophan degradation enzyme) is produced to degrade tryptophan in E. coli. From the foregoing, glycerol was attempted to use in the supplementing medium, in place of glucose. By doing so, the mechanism that when glucose in basal medium is exhausted, catabolite repression is lost, tryptophanase is produced, V I. -29tryptophan is used up and hence, trp promoter begins to work is expected. Furthermore, the addition rate of the supplementing medium is also varied depending upon proliferation of E. coli to attempt elaborated contrivances. Example 3 Fed-Batch System Part 2 The medium composition and culture conditiohs were identical with those of Example 1 except for adding tryptophan to basal medium in 30 mg/l. A supplementing medium (M9 medium containing g/l Casamino acid, 200 g/l glucose, 10 mg/l vitamin BI, 100 mg/l ampicillin and 5 mg/l IAA) began to add to the medium from 3 hours after and IAA was added 4 hours after. IAA was added in a concentration of 5 mg/l since an excess amount of IAA would inhibit proliferation of E. coli and hEGF production. For addition of the medium, PI tube pump (manufactured by Pharmacia Fine Chemicals Inc.) and a personal computer (PC 9801 VX41, manufactured by Nippon Electric Co., Ltd.). A rate of the addition was-programmed to make 49 changes in total during the addition. Proliferation of E. coli and hEGF production amount Sare shown in Fig. 7. S From about 5 hours after when the proliferation rate of E. coli decreased, hEGF production started and reached 70 mg/l 24 hours after. Cell proliferation was also increased to 9 at OD 550 From the foregoing results, it is noted that hEGF production amount increases as the cell amount increases. Thus, in order to perform culture in a higher density, medium composition and timing for addition were studied in detail. Specifically, amino acids necessary for proliferation of host E. coli were added to the medium and the carbon source in the supplementing medium was changed from glucose to glycerol. As described above, in the presence of glucose, tryptophan is consumed as E. coli proliferates but is not degraded by tryptophanase. It is thus attempted that: glucose and tryptophan are added to the initial supplementing medium to sufficiently 0 proliferate E. coli, while preventing trp promoter from acting. Then, IAA is added and at the same time, the supplementing medium S is changed to one containing glycerol so that tryptophan is S degraded to strengthen the action of IAA and hence the hEGF production amount is increased. Example 4 Fed-Batch System Part 3 Culture was carried out as follows, according to the 0 00 0 0 4 fed-batch system similar to the above. S Medium composition 1) Basal medium The following were supplemented to M9 medium. g/1 Casamino acid, 10 g/1 glucose, 50 mg/1 tryptophan, 'S 0.5 g/l proline, 1.0 g/l leucine, 10 mg/1 vitamin Bl, 100 mg/1 ampicillin and trace metal salts. 2) Supplementing medium 1 The following were supplemented to M9 medium. g/l Casamino acid, 300 g/l glucose, 50 mg/l tryptophan, L D r a a o ~P I I -31g/l proline, 5 g/l leucine, 10 ng/l vitamin B 1 100 mg/1 ampicillin and trace metal salts. 3) Supplementing medium 2 The following were supplemented to M9 medium. g/l Casamino acid, 300 g/l glycerol, 5 g/l proline, g/l leucine, 10 mg/l vitamin B 1 100 mg/1 ampicillin and trace metal salts. Culture condition Plasmid (host) was pBT23 (HB101). Culture volume (basal medium supplementing medium 1 supplementing medium 2) was 5 liters 0.5 liter 1.0 liter. Culture temperature was 37 0 C and pH was Aeration amount was 1.5 vvm (7.5 liters/min). Number of agitation was 900 rpm. Defoaming was automated (by dropwise addition of silicone type antifoaming agent). The timing for addition of medium: supplementing medium 1 was 0.5 to 6 hours (rate of addition was variable) after initiation of the culture and supplementing medium 2 was 6 to 24 hours (rate of addition was constant, 50 ml/hour) after initiation of the culture. IAA was added 6 hours after initiation of the culture and its concentration was 5 mg/l. preculture medium was identical with basal medium. An inoculation amount was A rate of supplying supplementing medium 1 was programmed to make 20 changes in total during the addition. Proliferation of I i t -I :r L I. i -32- E. coli and hEGF production amount are shown in Fig. 8. OD 550 24 hours after showed 42, indicating that higher density culture was achieved. hEGF was produced in an amount of 160 mg/l. 4. Brief Description of the Drawings Fig. 1 shows a sequence of the trp promoter, SD sequence and E. coli alkaline phosphatase signal peptide gene. Fig. 2 shows an hEGF gene sequence. O 0 0 Fig. 3 illustrates the progress of producing the secretion expression plasmid. Fig. 4 illustrates a sequence of Hind III-BamH I fragment of 0 o a the secretion expression plasmid pBT23. Fig. 5 shows the results of Example 1, wherein the abscissa represents a culture time (hour) and the vertical axis represents an amount (mg/l) of hEGF in medium: denotes culture in a fermenter and denotes flask culture. Fig. 6 shows the results of Example 2, wherein the abscissa represents culture time (hour) and the vertical axis represents S an amount (mg/l) of hEGF in medium: denotes culture in a fermenter and denotes flask culture. Fig. 7 shows the results of Example 3, wherein the abscissa represents culture time (hour) 'and the vertical axis represents an amount (mg/1) of hEGF and cell amount (expressed by OD 550 in medium: o denotes cell amount and denotes hEGF production. -33- Fig. 8 shows the results of Example 4, wherein the abscissa represents culture time (hour) and the vertical axis represents an amount (mg/l) of hEGF and cell amount (expressed by OD 550 in medium: o denotes cell amount and a denotes hEGF production. i r j Claims (10) 1. An expression vector for a protein, comprising: a first DNA sequence encoding said protein, said protein being hEGF, the gene being modified generally to provide codons used in Escherichia coli in high frequency, and repeat sequences associated with nucleotide secondary structure removed; a second DNA sequence encoding a signal peptide and operatively connected with the first DNA sequence in the upstream position; and a promoter sequence therefor, the promoter sequence substantially corresponding to an E. coli trp operon promoter having an ATG initiation codon. 2. A vector according to claim 1, wherein the signal peptide substantially corresponds to the E. coli alkaline phosphatase signal *a oo peptid. S 3. A vector according to claim I or 2, wherein the protein encoded has hEGF activity, or is a precursor therefor. 4. A cell comprising a vector according to any preceding claim. An expression system for the protein encoded by the vector of any of claims I to 3 comprising a culture of a suitable E. cli host for the vector. 6. An expression system according to claim 5, wherein protein production is induced by the addition of a tryptophan inhibitor. L-LL-LIIYII-LI~---LC~ i 35 7. An expression system according to claim 5, wherein protein production is controlled by the introduction of a tryptophan inhibitor. 8. A system according to claim 6 or 7, wherein the inhibitor is 3-indoleacrylic acid or an analogue thereof. 9. An expression system according to any of claims 5 to 8, which is a batch-feed system. In a genetic engineering technology which comprises performing a series of procedures through integrating a gene coding for an objective substance in a Svector, transforming host E. coli using this vector, culturing the thus obtained transformant at late log phase with the appropriate concentration of tryptophan, and then inducing with IAA, and 1 recovering and collecting the objective substance from Sthe culture solution: a process for producing hEGF characterized by and (b) below: said objective substance is hEGF; 4\I i^P li 36 in said procedure above, a region encoding an intact promotor containing ATG initiation codon for E. coli tryptophan (trp) operon and a gene encoding a signal peptide of E. coli alkaline phosphatase are integrated into an hEGF gene, the gene being modified generally to provide codons used in E. coli in high frequency, repeat sequences associated with nucleotide secondary structure being removed, and a complementary DNA in the upstream region and one or more termination codons and E. coli trpA transcription terminator are integrated in the downstream region. 11. A process for producing hEGF according to claim 10, wherein 3-indoleacrylic acid (IAA) is added during mid or late-log phase of culture, whereby the time period and amount of hEGF produced by host E. coli are controlled. 12. A process for producing hEGF according to claim 11, wherein said culture is high density culture utilizing batch-feed system in which a rate of addition is contrived. 13p. A process for roducing hEGF according to claim 12, wherein glucose or glycerol or glucose and then glycerol are used as carbon sources for a supplementing medium in the batch-feed system. DATED this 14th day of January 1991 NIPPON SHINYAKU COMPANY LIMITED By Their Patent Attorneys: GRIFFITH HACK CO sai ellows Institute of Patent Swhi Attorneys of Australia 'th f I. -^fs I. Hind IIIF trp Promotor AGC1TfTG GC AAATATTCTG AAATO AGCTGTTGACIAATTAATC ATCGA ACTAGTTA ACTAG I- -AAC CGTT TATAAGACTT TAC TCG ACAACTG TTAATTAGITAGCT TGAT CAATTG AT C SDSequence IF E. coil alkaline phosphatase TAC GC AAGTTICACGTAAAA AGGGTATC GACAATGAAACAAAGCACTAT TG CACTO GCACT ATGCGTTCAAGTGCATTTITTCC CATAGCTGTTACTTTGTTTCGTGATAACGTGAC COTGA ,igna. peptidle gene LcoRl CTTACCGTTACTGTTTACCCCTGTGACAAAAGCU-G I-- GAATGGICAATGACAAATGGGGACACTGTTTTC GL-CTTAA F I .1 ~N} 1 4 Ec-QRI X7ATT-CCGACTCTGIAATGTCC GCTOTCTC IATGATGGTTACTGTCTCICACGATGGTGTTTGT TGAGACTTACAGGjGCAGAGTACTAC CAAITGACAGACGTGCTAC CAICAAACA Shi~ hEGF gene ATIGTACATC GAAGCACTGGIATAAATAC:GCATGGtt&.ATTGTGTAGTTiGG TACAT CGGTGAA TA CATGTAG CTIT CGTGAC C TAT TTATGCIACQFlTAACAjAT CAACC ATGTAGIC CAT -1 Sal CGITTG CCAATACCGTG ATC ITGAAATGGTGGGAACTGICGCTGATAIGAGCT] UC AACGGTTAT IGGCACTAG5A CTT TACCAICC CTTGACGCGAkCTAT: C F I10.2. tI I, A, I I- 2/S H ii Ii I ~ii H ~I1 Amp Eco SHI SphI 1 Sad HindIll iEcoRi frp promotor E.coi ikatine phosphatase signal peptide gene p BT23 FI G. 3. Hind II II trp Promotor AGCTTTGGCAAATATTCTGAAATGAGCTGTTG ACAATTA ATC ATCG AACTAGTITAACTAG AAC CGT TTATMAGACT T TACT CGACAACTGT TMTTAGTAGCTTGAT C AATTGAT C LD~aqence I F-E. coli alkaline phosphatose TACGC AAGTTCACGTAAM AGGGTATCGACAATc3AAACAAAGCACTATT GCACT ciICACT ATGCGT TCAN3TGCATT TTT CC CATAGCTGTTACT TTGTTTCGTGATAACGTGAC CGTGA signal peptide gene r P- CTTACCGTTACTGTTTA CC CCTGTGACAAAAGCGAATTCCGACTCTGAATGTCCGCTGTC GAATGIGCAATGACAAATGGGGACACTGTTTTCGCTTAAG3GCTGAGACT TACAI3UCGACAG hEGF gene- TCATG ATGGTTACTGT CTG5C ACG ATGGTGTTTGTATGTAC ATCGAAGCACThGGATAAATA AGTACTACCAATGACAGACI3TGCTAC CACAAATACATGTAGCTT CGTGACCTAT T TAT Sph I CGCATG CAATTGTGTAGTTGGTTACATC G GTGAACGTTG CCAATACCGTGATCT GAAAT3 I3CGTACGT TAACACAT C AAC CAATOTAG C CACT TGCAACGGTTATG GCACTAGACTT TAC I SadI n-trpA terminator 7* B-omH1 GTGGGAACTGCGCTGATAC, AGJrCAGC C CGCCTAATGAGCGGGCTTTTTTT CTG CACCCTTGACGCGACTATCT CCAGTCGGGC3GATTACTCGCCCGAAAAAAAGACCTAG F 0. 4-. It II.. C C a CI (If I I a a -J I E .210 E 8 E %0 4 0 Culture Time F 0 ~-Glucose Mdition Culture Time F 0 .6. ii I I I 1-1-r -1 I I 1 I v I I Wd -Glycerol Addition--]- Cell Amount u 30- I 4- Li 200c hEGF Amun 0.110 0 2 4 6 8 10 24 Culture Time H 0 .7. Glucos e yeolAdin Ad ton--1yeo Addition 160 Cell Amount o-10 lO Cr 120= 8-I10 ////100E P '4- 4 0 60 LihEGF Amount -40 2 0 0 2 4 6 8 10 24 Culture Time FPI G8j AU38145/89A 1988-07-15 1989-07-14 Process for producing hegf Ceased AU622459B2 (en) Applications Claiming Priority (2) Application Number Priority Date Filing Date Title JP63177685A JPH0227993A (en) 1988-07-15 1988-07-15 Production of hegf JP63-177685 1988-07-15 Publications (2) Publication Number Publication Date AU3814589A AU3814589A (en) 1990-01-18 AU622459B2 true AU622459B2 (en) 1992-04-09 Family ID=16035314 Family Applications (1) Application Number Title Priority Date Filing Date AU38145/89A Ceased AU622459B2 (en) 1988-07-15 1989-07-14 Process for producing hegf Country Status (12) Country Link EP (1) EP0352839A3 (en) JP (1) JPH0227993A (en) KR (1) KR900001850A (en) CN (1) CN1039843A (en) AU (1) AU622459B2 (en) BE (1) BE1004361A4 (en) CH (1) CH679864A5 (en) FR (1) FR2634220A1 (en) GB (1) GB2221467B (en) HU (1) HUT52552A (en) IL (1) IL90799A0 (en) NZ (1) NZ229960A (en) Cited By (1) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title AU673870B2 (en) * 1990-11-08 1996-11-28 Japan Energy Corporation Hirudin mutant, production thereof, anticoagulant, secretory vector, and production of product from said microorganism Families Citing this family (5) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title WO1991005863A1 (en) * 1989-10-11 1991-05-02 Pitman-Moore Australia Limited Recombinant growth factors US5290920A (en) * 1992-04-16 1994-03-01 Allelix Biopharmaceuticals Inc. Method of purifying human epidermal growth factor AU6582594A (en) * 1993-04-26 1994-11-21 Dae Woong Pharmaceutical Co., Ltd. A novel gene coding human epidermal growth factor and process for preparing the same AU2002236197B2 (en) * 2002-02-05 2008-08-07 Geymonat S.P.A. Production process of recombinant placental growth factor EA025626B1 (en) * 2013-10-11 2017-01-30 Общество с ограниченной ответственностью "Протеиновый контур" PRODUCER OF HUMAN EPIDERMAL GROWTH FACTOR (rhEGF) Family Cites Families (9) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title AU542264B2 (en) * 1979-06-01 1985-02-14 G.D. Searle & Co. Plasmid vectors ZA811368B (en) * 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator US4453802A (en) * 1981-10-26 1984-06-12 Hughes Aircraft Company Evanescent-wave coupling device US4820642A (en) * 1983-04-04 1989-04-11 The Regents Of The University Of California Amplified expression vector CA1263619A (en) * 1984-10-09 1989-12-05 Ryuji Marumoto Dna, production and use thereof GB8515686D0 (en) * 1985-06-20 1985-07-24 Fujisawa Pharmaceutical Co Production of-human atrial natriuretic polypeptide JPH07110232B2 (en) * 1985-10-14 1995-11-29 株式会社日立製作所 Method and apparatus for collecting gene product of transgenic E. coli ATE84065T1 (en) * 1986-10-09 1993-01-15 Fujisawa Pharmaceutical Co EXPRESSION VECTOR FOR HUMAN INSULIN-LIKE GROWTH FACTOR-I. JPH01165382A (en) * 1987-12-19 1989-06-29 Tosoh Corp Method for controlling expression of gene 1988 1988-07-15 JP JP63177685A patent/JPH0227993A/en active Pending 1989 1989-06-29 IL IL90799A patent/IL90799A0/en unknown 1989-06-30 CN CN89104571A patent/CN1039843A/en active Pending 1989-07-07 EP EP89201822A patent/EP0352839A3/en not_active Withdrawn 1989-07-10 CH CH2565/89A patent/CH679864A5/fr not_active IP Right Cessation 1989-07-11 GB GB8915837A patent/GB2221467B/en not_active Expired - Fee Related 1989-07-12 FR FR8909393A patent/FR2634220A1/en not_active Withdrawn 1989-07-13 BE BE8900763A patent/BE1004361A4/en not_active IP Right Cessation 1989-07-14 HU HU893577A patent/HUT52552A/en unknown 1989-07-14 AU AU38145/89A patent/AU622459B2/en not_active Ceased 1989-07-15 KR KR1019890010157A patent/KR900001850A/en not_active Application Discontinuation 1989-07-17 NZ NZ229960A patent/NZ229960A/en unknown Cited By (1) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title AU673870B2 (en) * 1990-11-08 1996-11-28 Japan Energy Corporation Hirudin mutant, production thereof, anticoagulant, secretory vector, and production of product from said microorganism Also Published As Publication number Publication date GB2221467A (en) 1990-02-07 BE1004361A4 (en) 1992-11-10 AU3814589A (en) 1990-01-18 EP0352839A2 (en) 1990-01-31 CH679864A5 (en) 1992-04-30 FR2634220A1 (en) 1990-01-19 GB8915837D0 (en) 1989-08-31 EP0352839A3 (en) 1990-05-02 CN1039843A (en) 1990-02-21 KR900001850A (en) 1990-02-27 JPH0227993A (en) 1990-01-30 IL90799A0 (en) 1990-01-18 GB2221467B (en) 1992-08-26 HUT52552A (en) 1990-07-28 NZ229960A (en) 1992-07-28 Similar Documents Publication Publication Date Title US5310663A (en) 1994-05-10 Affinity peptides JP3899121B2 (en) 2007-03-28 Expression method for producing apolipoprotein AI-M EP0047600B1 (en) 1992-02-26 Bovine pre-growth and growth hormone EP0035384B1 (en) 1987-06-10 Deoxynucleotide linkers to be attached to a cloned dna coding sequence US4769326A (en) 1988-09-06 Expression linkers US5168049A (en) 1992-12-01 Production of streptavidin-like polypeptides US5100784A (en) 1992-03-31 Process for the preparation of mature human serum albumin AU622459B2 (en) 1992-04-09 Process for producing hegf US7264946B2 (en) 2007-09-04 Thermoanaerobacter brockii alcohol dehydrogenase promoter for expression of heterologous proteins US4828988A (en) 1989-05-09 Hybrid polypeptides comprising somatocrinine and alpha1 -antitrypsin, method for their production from bacterial clones and use thereof for the production of somatocrinine EP0321940B1 (en) 1994-02-16 An improved method for the preparation of natural human growth hormone in pure form EP0170266A2 (en) 1986-02-05 Process for producing protein, and vector, recombinant DNA and transformant used therefor EP0046669B1 (en) 1984-10-24 Somatostatin or somatostatin precursors JP2552650B2 (en) 1996-11-13 Novel expression control sequence JP3315827B2 (en) 2002-08-19 Method for producing active human ALT EP0314184B1 (en) 1995-12-13 Expression plasmids US5434245A (en) 1995-07-18 Polypeptides and method for preparing the same JPH02257883A (en) 1990-10-18 Preparation of signal peptide, dna sequence vector, bacterium and polypeptide periphery EP0295285B1 (en) 1994-04-06 Method for the production of bovine growth hormone using a synthetic gene US5139935A (en) 1992-08-18 Method of regulating expression of a foreign gene by controlling the sugar concentration in a medium and a process of producing a foreign product thereby US5145782A (en) 1992-09-08 DNA expression vector suitable for direct expression of a foreign gene GB2214508A (en) 1989-09-06 Plasmid vector for the efficient expression of foreign genes fused with newly conceived transcriptional and translational signal sequences. CA1200774A (en) 1986-02-18 Expression linkers KR860001922B1 (en) 1986-10-25 Process for preparing a dna transfer vector containing a seqaeme for bovine growth hormone JPH0650989B2 (en) 1994-07-06 Method for producing anticancer or antitumor protein
Download PDF in English